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ABSTRACT
 
Low aqueous solubility of the newly discovered drug 
possesses a great challenge for the development of 
dosage form with suitable applicability. Self-
Emulsifying Drug Delivery System (SEDDS) provides 
an excellent alternative for increasing solubility of 
lipid soluble drugs which is achieved by 
microemulsion through chemical means. Self-
Emulsifying drug delivery system is the blend of 
surfactants and oils which are isotropic in nature. It 
also includes co-solvents which upon gentle agitation 
gets emulsified under conditions mimicking to those 
which would be encountered in the gastrointestinal 
tract. This article discusses mechanism components, 
pharmaceutical aspects, patents and recent work done 
on SEDDS. 
 
Keywords: Hydrophilic lipophilic balance, self-micro 
emulsifying drug delivery system, self-emulsifying 
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INTRODUCTION 
In drug discovery process, most of about 
new drugs contender’s exhibit low 
solubility in water, which leads to poor 
bioavailability, high intra subject/inter 
subject variability and lack of dose 
proportionality. Additionally, oral drug 
delivery of copious drugs is stuck owing to 
their high hydrophobicity. Therefore, there 
is need for producing suitable formulations 
to improve the solubility and 
bioavailability of such drugs. Amongst 
commercially available formulation one of 
the most prevalent approaches for getting 
rid out of this problem is self-emulsifying 
drug delivery systems (SEDDS). SEDDS 
have been shown to be reasonably 
successful in improving the oral 
bioavailability of poorly water-soluble and 
lipophilic drugs. Traditional SEDDS 
preparations involves dissolution of drugs 
in oils and their blending with suitable 
solubilizing agents. In the oral formulation 
of such above mentioned compounds, a 
number of attempts are made such as 
decreasing particle size, use of wetting 
agents, co precipitation, and preparation of 
solid dispersions have been made to 
modify the dissolution profile and thereby 
improve the absorption rate. Recently, 
much attention has focused on lipid-based 
formulations to improve the bioavailability 
of poorly water-soluble drugs. Among 
many such delivery options like 
  
20 Page 19-44 © MAT Journals. All Rights Reserved 
 
Recent Trends in Pharmaceutical Sciences and Research  
Volume 2, Issue 1 
 
incorporation of drugs in oils, surfactant 
dispersion, emulsions and liposomes, one 
of the most popular approaches are the 
self-emulsifying drug delivery systems 
(SEDDS). To address these problems, 
supersaturated self-emulsifying drug 
delivery systems (S-SEDDS) have been 
investigated, as alternative approaches. 
Such systems require the solidification of 
liquid self-emulsifying (SE) ingredients 
into powders/nano particles to create 
various solid dosage forms (SE tablets and 
SE pellets and so on). Thus, S-SEDDS 
combine the advantages of SEDDS i.e. 
enhanced bioavailability and solubility 
with solid dosage forms i.e., convenience 
of process control, low production cost, 
high stability and reproducibility, better 
patient compliance. Till the date, there 
have been some studies that mainly 
emphasis on the preparation and 
characterization of solid SE dosage form, 
yet moderately few that introduce S-
SEDDS in a general way, especially with 
respect to dosage form development and 
preparation techniques [1]. 
 
What is self-emulsified drug delivery 
system? 
Self-Emulsifying drug delivery system is 
the blend of surfactants and oils which are 
isotropic in nature. It also includes co-
solvents which upon gentle agitation gets 
emulsified under conditions mimicking to 
those which would be encountered in the 
gastrointestinal tract [2]. 
 
Need of SEDDS 
Oral deliveries of poorly water-soluble 
compounds are to pre-dissolve in a 
suitable solvent and fill the formulation 
into capsules. Foremost advantage of this 
approach is that pre-dissolving the 
substances, overcomes the initial rate 
limiting step of particulate dissolution in 
the aqueous environment within the GI 
tract. Though, a potential problem is that 
the drug may be precipitated out of 
solution when the formulation disperses in 
the GI tract, particularly if a hydrophilic 
solvent is used e.g. polyethylene glycol. If 
the drug candidate is dissolved in a lipid 
vehicle there is probably less potential for 
precipitation on dilution in the GI tract, as 
partitioning kinetics will favor the drug 
present in the lipid droplets. Another 
strategy for poorly soluble drugs is to 
formulation a solid solution using a water-
soluble polymer to aid solubility of the 
drug compound. For example 
Polyvinylpyrrolidone (PVP) and 
polyethylene glycol (PEG 6000) have been 
widely used for the preparation of solid 
solutions with poorly solubility of drugs. 
One potential problem with this class of 
formulation is that the drug may favor a 
more thermodynamically stable state, 
which can result in the compound 
crystallizing in the polymer matrix. Thus, 
the physical stability of such formulations 
needs to be measured using different 
techniques such as differential scanning 
calorimetry or X-ray crystallography. In 
this class of case SEDD system is a good 
option [3]. 
 
Advantages of SEDDS 
 Enhanced oral bioavailability enabling 
reduction in dose. 
 More consistent temporal profiles of 
drug absorption. 
 Selective targeting of drugs in the 
direction of specific absorption 
window in GIT. 
 Protection of drugs from the unfriendly 
environment in gut. 
 Control of delivery profiles. 
 Reduced variability including food 
effects. 
 Protective of sensitive drug substances. 
 High drug payloads. 
 Liquid or solid dosage forms [4−6]. 
 
Disadvantages of SEEDS 
The main disadvantage for the 
development of self-emulsifying drug 
delivery systems (SEDDS) and other lipid-
based formulations is:  
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Lack of in vitro models for evaluation of the 
formulations for SEEDS. Traditional 
dissolution methods are not merely working, 
because these formulations potentially are 
dependent on digestion prior to their release 
of the drug to overcome, an in vitro model 
that simulates the digestive processes of the 
duodenum has been developed. This in vitro 
model needs additional development and 
validation to be performed before its strength 
can be evaluated. Further the development 
will be carried out on the origin of in vitro-in 
vivo correlations and therefore different 
prototype lipid-based formulations needs to 
be developed and tested in vivo in a suitable 
animal model. Future studies will address the 
development of the in vitro model [7]. 
 
Lipid Formulation Classification 
System 
Due to large number of possible 
combinations that might be used to gather 
lipid-based formulations especially self-
emulsifying systems, a classification 
system (Lipid Formulation Classification 
System-LFCS) was introduced by Pouton 
in 2000 and was later updated in 2006. 
This system briefly classifies lipid-based 
formulations into four types as per their 
composition and the possible effect of 
dilution and digestion on their ability to 
prevent drug precipitation. The main role 
of lipid formulation classification system 
is to facilitate interpretation of in vivo 
studies more readily and identification of 
most suitable formulation for specific 
drugs with reference to their 
physicochemical properties. Table 1 shows 
typical composition of various types of 
lipid formulations and properties of lipid-
based formulations. 
 
Table 1: Lipid formulation classification system. 
Typical Composition Class I Class Ii Class Iii A Class Iii B Class Iv 
Triglycerides 
(%W/W) 
100 40-80 40-80 <20 - 
Surfactants - 
15-20 
HLB<12 
20-40 
HLB>12 
20-50 
HLB>12 
0.20 
HLB<12 
30-80 
HLB>12 
Hydrophobic cosolvents 
(%W/W) 
- - 0-40 20-50 40-60 
Particle size Coarse 100-250 100-250 50-100 <50 
Significance of aq. dilution 
Limited 
importance 
Solvent 
capacity 
unaffected 
Some 
loss of 
solvent 
capacity 
Significant 
phase 
changes 
High risk of 
precipitation 
Significance of dispersibility 
Crucial 
requirement 
Not crucial 
but likely to 
occur 
Not crucial 
but maybe 
inhibited 
Not required 
Not 
required 
 
Class I formulations comprise formulations 
solubilized drug in triglycerides and/or mixed 
glycerides or in an oil-in water emulsion 
stabilized by low concentration of 
emulsifiers. 
 
These method possess poor aqueous 
dispersion at starting level, and require 
pancreatic lipase in the GIT to produce 
some of the amphiphilic lipid products in 
high amount and they promote drug 
transfer into the colloidal aqueous phase. 
 
Class I formulations therefore are a good 
option for drugs having sufficient 
solubility in oils. Valproic acid has been 
formulated in soft gelatin capsule 
containing corn oil as lipidic component. 
Class II formulations are referred to as 
SEDDS. SEDDS are isotropic mixtures of 
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lipids and lipophilic surfactants 
(HLB<12), co-surfactant and the drug. 
They form oil-in-water emulsions under 
mild agitation following dilution with 
aqueous phases. Self-emulsification is 
generally obtained at surfactants contents 
above 25% (w/w). But at higher 
surfactants concentration (greater than 50-
60% w/w) the progress of emulsification 
may be hindered by the formation of 
viscous crystalline. Gels at the oil/water 
interface no Class II formulation has been 
marketed till date. 
 
Class III formulations are commonly 
referred as self-micro emulsifying drug 
delivery systems (SMEDDS). They 
comprise of oils, hydrophilic surfactants 
(HLB>12) and co-solvents such as 
ethanol, propylene glycol and polyethylene 
glycol. Class III formulations are further 
divided into Class IIIA and Class IIIB 
formulations. Other includes more amount 
of hydrophilic surfactants and co-solvents, 
contains low lipid content, as compared to 
Class IIIA. Class IIIB there is more 
chances of drug precipitation, if there is 
high hydrophilic surfactants and co-
solvents. The distinction between SEDDS 
(Class II) and SMEDDS (Class III) 
formulations is commonly made on the 
globule size and optical clarity of the 
resultant dispersion. SEDDS formulations 
form opaque dispersions with globule sizes 
> 100nm whereas, SMEDDS disperse to 
give optically clear or slightly opalescent 
dispersions with globule sizes < 100nm. 
E.g.: Class III formulation is “Neoral" 
(Novartis) cyclosporine formulation which 
includes corn oil glycerides, Cremophor 
RH40, glycerol, propylene glycol and 
ethanol". 
 
Class IV category was added to the LFCS 
by Pouton in 2006 Class IV formulations 
are devoid of oils and represent the most 
hydrophilic formulations. They produce 
fine dispersions when introduced to 
aqueous media. A Class IV formulation is 
useful for drugs which are hydrophobic 
but not lipophilic E.g.: Class IV 
formulation is “Aqenerase'" 
(GlaxoSmithKline) a capsule formulation 
of the HIV protease inhibitor amprenavir 
which contains PEG 400 and propylene 
glycol as cosolvents and tocopherol 
polyethylene glycosuccinate (TPGS) as a 
surfactant [8, 9]. 
 
 
Figure 1: Typical representation of lipid formulation classification system. 
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Biopharmaceutical classification system (BCS) 
Table 2: Biopharmaceutical classification system. 
BCS class 
Aqueous 
Solubility 
Membrane 
permeability 
Hurdles overcome by 
SEDDS 
I High High Enzymatic degradation, gut wall efflux. 
II Low High Solubilization, bioavailability. 
III High Low 
Enzymatic degradation, gut wall efflux, 
bioavailability. 
IV Low Low Solubilization, bioavailability. 
 
Lipid based formulations suggests a 
potential display place for improving oral 
bioavailability of drugs which falls under 
Class II and Class IV of 
Biopharmaceutical Classification System 
(BCS). A primary indication of the 
potential utility of lipid-based formulation 
can be obtained by assessing the drug 
lipophilicity (Log p) and its solubility in 
pharmaceutically-acceptable lipid 
excipients, which should be adequate to 
allow the entire dose of the drug in single 
dosage unit. Additional indicator of the 
potential for success of a lipid-based 
formulation is the adherence of a strong 
positive food effect when the drug is 
administered with a fatty meal as 
contrasting to dosing in the tasted". For 
lipophilic drug compounds that exhibit 
dissolution-rate-limited absorption, 
SEDDS can offer an improvement in rate 
and extent of absorption resulting in 
reproducible blood time profiles. The 
systems can help in overcoming the 
below-mentioned problems of all the 
categories of BCS class drugs, as shown in 
Table 2. 
 
SEDDS usually provide advantage of 
increased drug loading capacity when 
compared with lipid solutions as the 
solubility of poorly water-soluble drugs 
with intermediate partition coefficients 
(2<log p<4) are typically low in natural 
lipids and much greater in amphiphilic 
surfactants, co-surfactants and co-solvents. 
LogP is the prime criterion for design of 
lipidic systems. High LogP (greater than 4) 
values are desirous for lipidic systems. 
Next physicochemical criteria that play an 
important role are melting point and dose. 
Low melting point and low dose are 
desirable for development of lipidic 
systems. 
 
This bioavailability enhancing property 
has been associated with a number of in 
vivo properties of lipidic formulation 
including: 
 The formation of fine dispersions and 
micellar suspensions to prevent 
precipitation and recrystallisation of 
the drug compound. 
 The ability of certain lipid compounds 
and their metabolites to initiate 
changes in the gastrointestinal fluid to 
favor improved drug absorption. 
 The inhibition of cellular efflux 
mechanisms, which keep drugs out of 
the circulation [10]. 
 
Biopharmaceutical Aspects 
The ability of lipids and/or food to 
enhance the bioavailability of poorly water 
soluble drugs has been comprehensively 
reviewed and the interested reader is 
directed to these References for further 
details. The mechanism of lipids 
enhancing bioavailability is not clearly 
understood, there are numerous potential 
mechanisms including: 
 
In vivo solubilization of drug: The 
presence of lipids in the GIT stimulates an 
increase in the secretion of bile salts (BS) 
and endogenous biliary lipids including 
phospholipids (PL) and Cholesterol (CH), 
leading to the formation of BS/PLICH 
intestinal mixed micelles and an increase 
in the solubilization capacity of the GI 
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mixed micelles and an increase in the 
solubilization capacity of the GIT. But, 
intercalation of administered (exogenous) 
lipids into these BS structures either 
directly or through secondary digestion, 
leads to swelling of the micellar structures 
and an additional increase in solubilization 
capacity 
 
Prolongation of gastric residence time: 
Lipids in the GI tract provoke delay in 
gastric emptying, i.e., gastric transit time is 
increased. As a result, the residence time 
of the Co-administered lipophilic drug in 
the small intestine increases. This enables 
better dissolution of the drug at the 
absorptive site, and thereby improves 
absorption. 
 
Promotion of intestinal lymphatic 
transport: For highly lipophilic drugs, 
lipids may enhance the extent of lymphatic 
transport and increase bioavailability 
directly or indirectly via a reduction in first 
pass metabolism. 
 
Affecting intestinal permeability: A 
variety of lipids have been shown to 
change the physical barrier function of the 
gut wall, and hence, to enhance 
permeability. 
 
Reduced metabolism and efflux activity: 
Recently, certain lipids and surfactants 
have been shown to reduce the activity of 
efflux transporters in the GI wall, and 
hence increase the fraction of drug 
absorbed. Because of the interplay 
between P-gp and CYP3A4 activity this 
mechanism may reduce intra-enterocyte 
metabolism as well Examples of 
surfactants with P-gp inhibitory activity 
include Cremophor EL, labrasol, 
Polysorbate 80, polysorbate 20. 
 
Lipid digestion and drug solubilization 
in the GIT 
Lipid based dosage (SEDDS) form is 
initially acted upon by gastric lipase. The 
gastric lipase digests exogenous dietary or 
formulation lipid. The gentle agitation and 
gastric emptying aids in 'emulsification 
prior to entry into duodenum. Within the 
small intestine, pancreatic lipase together 
with its co-factor co-lipase completes the 
breakdown of dietary glycerides to 
diglycerides, monoglyceride and fatty 
acid. The presence of exogenous lipids in 
the small intestinal so stimulates secretion 
of endogenous biliary lipids including bile 
salt (BS), phospholipids and cholesterol 
from the gall bladder. In the presence of 
elevated BS concentrations, there is an 
incorporation of products of lipid digestion 
into series of colloidal structures which 
includes multilamellar and unicameral 
vesicles, mixed micelles. Collectively 
these species expand the solubilization 
capacity of the small intestine for lipids 
and drugs. 
 
Circulatory uptake of drug 
Both the lymph and blood vessels are 
present in the mucous membrane 
underlying the intestinal absorptive cells 
(enterocytes) of the intestine. The rate of 
fluid flow in the portal blood is 
approximately 500 times higher than that 
of intestinal lymph in contrast, following 
the uptake into the enterocytes, fatty acid 
(FA) and monoglyceride (MG) digestion 
products are resynthesized into triglyceride 
(TG) and assembled into colloidal 
lipoproteins (LP) within endoplasmic 
reticulum. These LP are exocytosis across 
the basolateral membrane of the 
enterocytes and preferentially enter the 
mesenteric lymph vessels due to their size 
which preludes easy diffusion across the 
vascular endothelium. Highly lipophilic 
drug (log P>5, and long chain TG 
solubility >50mg/g) may therefore access 
the intestinal lymph via association with 
developing lipoproteins [10]. 
 
Approaches of Delivery Systems 
Hydrophobic drugs can often be dissolved 
in SEDDS allow in them to be 
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encapsulated as unit dosage forms for per 
oral administration generally; self-
emulsifying formulations form a fine 
emulsion when exposed to aqueous media 
under conditions of gentle agitation. The 
resulting oil-in-water emulsions are 
thermodynamically stable due to the 
relatively small volume of the dispersed 
oil phase, the narrow range of droplet size 
distribution and the polarity of the 
droplets. Oral administration of SEDDS, 
which can be conveniently encapsulated in 
soft gelatin capsules, the digestive motility 
of the stomach and the intestine provide 
the agitation necessary for self-
emulsification, Improvement in the extent 
and rate of absorption of lipophilic 
compounds from self-emulsifying 
formulations is new as compared to 
traditional oral formulations. The potential 
of lipoids self-emulsifying drug delivery 
systems (SEDDS) and self-micro 
emulsifying drug delivery systems 
(SEDDS) for improving the extent and 
reproducibility of the oral absorption of 
Halofantrine is investigated as such and 
formulations have been reported to 
improve the rate and extent of absorption 
of lipophilic drug. 
 
In recent study, the self-emulsifying 
properties of Glyceryl Monooleate (GMO) 
formed a hydrophobic core, presumably 
micellar, to enhance the solubility of 
Paclitaxel (PTX) and provide a foundation 
for chitosan aggregation. 100% loading 
and entrapment efficiencies of PTX in this 
formulation are credited to the self-
emulsifying properties of-mono glycerides 
(like GMO), a polar lipid with poor water 
solubility that shows properties resembling 
non-ionic surfactants have been 
comprehensively described [11].
 
DIFFERENCE BETWEEN SELF-EMULSIFIED DRUG DELIVERY SYSTEM AND 
SELF-MICRO EMULSIFIES DRUG DELIVERY SYSTEM [12] 
Table 3: Difference between SEDDS and SMEDDS. 
SR. NO. SEDDS SMEDDS 
1 
Binary composition with the drug and lipid 
Excipients able to self-emulsifying in contact 
with GI fluid. 
Contains drug, surfactant, cosurfactant and oil 
for lipid phase. 
2 
Lipid droplet size in the dispersion range from 
200nm-5-micron, dispersion has turbid 
appearance. 
Lipid droplet size in the dispersion range from 
less than 200nm, dispersion has an optically 
clear to translucent appearance. 
3 
SEDDS are not thermodynamically stable due 
to larger particle size and co-surfactants are 
not added in formulation. 
SMEDDS are thermodynamically stable due to 
smaller particle size and co surfactants are 
added in formulation. 
4 Concentration of oil is 40-80%. Concentration of oil is less than 20%. 
5 SEDDS formed using surfactant HLB<12. SMEDDS formed using surfactant HLB>12. 
6 
Optimization of SEDDS is done by using 
Ternary phase diagram. 
Optimization of SMEDDS is done by using 
pseudo ternary phase diagram. 
 
COMPOSITION AND 
FORMULATION OF SEDDS 
Excipients Used in Self-Emulsification 
Drug Delivery System 
Self-emulsifying solid dosage contains 
mainly oil, surfactant, co surfactant, filler 
etc. there are many oils either as main 
ingredients or use as vehicles for varied 
dosage forms, many oils were under study 
medium chain fatty acid ester or a 
medium/long chain saturated, partially 
unsaturated or unsaturated hydrocarbon, in 
liquid, semisolid or solid form at room 
temperature. 
 
The simplest and most desirable 
formulation may well be a simple oil 
solution which is self-emulsified in the gut 
during digestion. For toxicity reason, these 
days research focuses on the use of non‐
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ionic surfactant with relatively hydrophilic 
lipophilic balance (HLB) value. We 
acknowledge that reviews have been 
presented earlier on excipients used in 
SEDDS however there are some critical 
studies conducted since those reviews are 
prepared. Emphasis is placed on the new 
excipients. 
 
Polyglycolyzed glycerides (PGG) of fatty 
acid varying amount and Polyethylene 
glycol (PEG) of varying chain length 
possess varied HLB value, they used to 
improve bioavailability of poor water 
soluble drugs with vegetable oils. 
 
According to the manufacturer, these 
products are derived from selected, high 
purity, food-grade vegetable oils which are 
reacted with pharmaceutical grade PEG 
and there-fore expected to be well 
tolerated by the body. Recently, the 
emulsification and solubilization 
properties of Polyglycolyzed glyceride-
based oils, Labrafil oils (Table 4), in self-
emulsifying formulations have been 
investigated using Tween 80 and Tween 
20 as surfactants. 
 
E.g. Danazol (a poorly water-soluble 
compound with an estimated aqueous 
solubility of <1 g/mL and log P = 4.2) and 
mefenamic acid (a non-steroidal anti-
inflammatory drug with an aqueous 
solubility of 40 g/mL and log P = 5.3) is 
selected as the model drugs. The more 
hydrophilic oil-surfactant mixtures showed 
greater emulsification ability and a smaller 
particle size. A linear relationship is 
observed between the hydrophile-lipophile 
balance (HLB) of the mix and the 
solubility of both danazol and mefenamic 
acid, with more hydrophilic mixtures 
producing greater drug solubility [13, 14].
 
Table 4: Physiochemical properties and main acid composition of labrafil oils. 
Oil Main fatty acid PEG group HLB 
Water 
solubility at 20
0
C 
Viscosity at 
20
0
C 
Labrasol (430) 
Caprylic 
(C8) 
(50-80%) 
+ 
Capric 
(20-80%) 
PEG 400 14 Soluble 80-110 
Labrafac 
CM 10 
(440) 
Caprylic 
(C8) 
50% 
+ 
Capric 
50% 
PEG 200 10 Dispersible 0-90 
Labrafil WL 
Oleic acid 
(58-68%) 
+ 
Linolenic acid 
(53-63%) 
PEG 400 6 Dispersible 80-120 
 
Self-Emulsification Nature 
For emulsification process there are 
certain criteria as follows: nature of the 
oil/surfactants, concentration of 
surfactants, ratio of oil/surfactant and 
temperature. The affluence of 
emulsification process could be related to 
the ease of hydrophilic compound to 
penetrate into the liquid crystal or gel 
phases. To characterize the self- 
emulsifying process there are certain 
parameters as follow: rate of 
emulsification, charge of droplets, 
emulsion size. Main parameter form this is 
droplet size as it will determine the rate 
and extent of drug release and absorption. 
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To obtain positively charged emulsion 
droplet addition of small cationic lipid 
(oleylamine) will give better result. E.g.: 
The oral bioavailability of progesterone is 
significantly enhancing rate by forming 
positively charged emulsion in comparison 
to the corresponding negatively charged 
formulation. The self-emulsifying 
technique is depending on nature of the 
oil– surfactant pair, surfactant 
concentration and the temperature at which 
self-emulsification occurs. 
 
Composition 
 Oil 
 Surfactant 
 Co solvents/Co surfactants 
 Others components 
 
Oils 
The oil represents the most important 
Excipients in the SEDDS formulation. 
Indeed it can solubilize relevant amount of 
the poorly water soluble drug. Both long-
chain triglyceride (LCT) and medium 
chain triglyceride (MCT) oils with 
different degrees of saturation have been 
used in the design of SEDDS. In SEDDS 
we can use different types of oil for 
examples monoglycerides, diglycerides, 
triglycerides of fatty acids, fatty alcohols, 
vegetable oils, mineral oils, refined animal 
oils E.g. - Corn oil, olive oil, soybean oil, 
hydrolyzed corn oil etc. 
 
Nature of oil is very important in the 
formation of SEDDS. Chemicals structure 
of the oil components and interactions of 
these components with the various 
enzymes, surfactants and proteins 
associated with digestion and absorption 
process, for example, fatty acid chain 
length is important factor for chylomicron 
formation. Liquid crystal formation from 
oil depends on oil polarity, which would 
influence the emulsification process [13, 
14]. 
 
Surfactants 
Surfactant molecules may be classified 
based on the nature of the hydrophilic 
group within the molecule. The four main 
groups of surfactants are classified in 
Table 5. 
 
Table 5: Classification of surfactants with examples. 
Type of Surfactants Charge on surface Groups Examples 
Anionic surfactants Negative 
Hydrophilic groups like 
carboxyl 
(RCOO), Sulphonate (RSO3-
) or sulphate (ROSO3). 
Potassium laurate, sodium 
lauryl sulphate 
Cationic surfactants Positive Hydrophilic 
Quaternary ammonium 
halide. 
Ampholytic surfactants 
 
Both Negative and 
Positive 
Hydrophilic Sulfobetaines. 
Nonionic surfactants 
(zwitterionicsurfact ants) 
No charge 
Hydrophilic group 
Hydroxyl or polyoxyethylene 
(OCH2CH2O). 
Sorbitan esters 
(Spans), polysorbat es 
(Tweens). 
 
Surfactants are having property of either 
dissolve or solubilize in high amount of 
hydrophobic drug compounds. So called 
they are amphiphilic nature. 
 
Surfactants, particularly with high 
hydrophilic lipophilic balance (HLB) 
values that is Nonionic surfactant are used 
more in SEEDS formulation. In SEEDS 
formulation, the surfactant strength is 
between 30−60% w/w. High HLB and 
hydrophilicity contribute the immediate 
formation of o/w droplets. They also have 
rapid spreading in the aqueous media. 
  
28 Page 19-44 © MAT Journals. All Rights Reserved 
 
Recent Trends in Pharmaceutical Sciences and Research  
Volume 2, Issue 1 
 
Co solvents 
Co-solvents such as ethanol, propylene 
glycol (PG) and polyethylene glycol 
(PEG) are most suitable for oral 
delivery of drug, also they permit 
dissolution of surfactants either 
hydrophilic or lipophilic respectively. 
These solvents can even act as co 
surfactants in micro emulsion systems. 
In turn there is disadvantage of alcohols 
and other volatile co-solvents that they 
evaporate into the shells of the soft 
gelatin or hard sealed gelatin capsules in 
predictable SEDDS leading to drug 
precipitation [13, 14]. Example: Span 
20, Span 80, Capryol 90.
 
Table 6: Examples of oils, surfactants and co-solvents. 
Lipids Oils Surfactants Co-solvents 
Miglyol 812 Cotton seed oil Polysorbate 20 (Tween 20) Span 20 
Tricaprylin Soybean oil Polysorbate 80 (Tween 80) Span 80 
Labrafac CC Corn oil 
D‐alpha Tocopheryl polyethylene 
glycol 
1000 succinate (TPGS) 
Capryol 90 
Ethyl oleate Sunflower oil 
Polyoxy‐35‐castor oil(Cremophor 
RH40) 
Lauroglycol 
Captex 355 Castor oil 
Polyoxy‐40‐ hydrogenated castor 
oil(Cremophor RH40) 
Transcutol 
Isopropyl myristate Sesame oil Labrasol Capmul 
Labrafac PG Peanut oil Labrafil M1944CS Ethanol 
Peceol Labrafac Labrafil M2125CS Polypylene glycol 
Akoline MCM Labrafil Lauroglycol 90 
Polyethylene glycol 
 
Maisine 35-1 Vegetable oil  Transcutol P 
 
Other Components 
Other components might to be pH 
adjusters, flavors, and antioxidant agents. 
Indeed a characteristic of lipid products, 
particularly those with unsaturated lipids 
show peroxide formation with oxidation. 
Free radicals such as ROO, RO, and OH 
can damage the drug and induce toxicity. 
Lipid peroxides may also be formed due to 
auto-oxidation, which increases with 
unsaturation level of the lipid molecule. 
Hydrolysis of the lipid may be accelerated 
due to the pH of the solution or from 
processing energy such as ultrasonic 
radiation. Lipophilic antioxidants are 
required to stabilize the oily content of the 
SEDDS E.g.α-tocopherol, propylgallate, 
ascorbyl palmitate [13, 14]. 
 
Absorption of Drug 
Most of the dietary lipids are triglycerides 
which are fatty acids ester of glycerol. 
Generally, lipase digests the fat. On 
ingestion of the triglycerides a course 
emulsion is believed to form in stomach 
with dietary phospholipids, proteins and 
polysaccharides are believed to be potent 
emulsifiers, forming a monolayer around 
the triglyceride droplets. In stomach about 
10 to 40% of normal fat digestion takes 
place which involves hydrolysis to 
diglycerides and fatty acids. This process 
is being done by human gastric lipase 
(HGL). Short chain fatty acids may 
dissolve into the aqueous phase followed 
by absorption across the stomach mucosa, 
while longer chain acids may remain 
incorporated in the emulsion droplet core. 
The emulsion passes to the upper section of 
the large intestine where particle size 
reduction of the droplets takes place due to 
the presence of a range of emulsifying agent 
such as monoglycerides, bile salts, lecithin 
and lysolecithin, cholesterol, yielding an 
approximate size range of 0.5 to 1 μm. Fig. 2 
describes the intestinal absorption.
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Figure 2: Intestinal pre absorptive process. 
 
The mechanism responsible for such 
efficient emulsification of ingested 
triglycerides are not yet clear, although In 
vitro studies have shown that mono olein, 
oleic acid and monomeric bile salts may at 
intestinal pH significantantly lower the 
interfacial tension of triolein droplets there 
by allowing emulsification to take place 
under condition of comparatively low 
shear. Then lipolysis takes place via 
triacylglycerol acyl hydrolase, typically 
referred to as pancreatic lipase. The 
bioavailability enhancement of a drug is 
generally depending on its dissolution 
behavior or particle charges of the drug 
molecule [15]. 
 
 
Figure 3: Distribution of drug solubilization in an emulsion. 
 
Mechanism of Self-Emulsification 
According to therapeutic consideration of 
Reiss, self-emulsification occurs only 
when the entropy changes. This favors that 
dispersion is greater than the energy 
required to increase the surface area of the 
dispersion respectively. 
 
In emulsification process the free energy 
(ΔG) associated is given by the equation: 
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ΔG = ΣNiπri2σ                                        1 
The free energy of the emulsion is directly 
function of energy which is required to 
create a new surface between the water 
and oil phase and which can be described 
by the equation. 
 
Where, ΔG is the free energy associated 
with the process (ignoring the free energy 
of mixing). 
 
N is the number of droplets of radius r and 
s represents the interfacial energy. The 
emulsion possess two phases which 
separate with time to reduce the interfacial 
area, and consequently, the emulsion is 
stabilized by emulsifying agents, which 
forms a monolayer of emulsion droplets, 
and hence reduces the interfacial energy, 
as well as providing a barrier to prevent 
coalescence [16, 17]. 
 
Solid Carriers 
These solid carriers have property to 
absorb liquid/semisolid formulation as 
self-emulsifying system (SES). It is a 
simple procedure, where SES is 
incorporated into a free-flowing powder 
material which has adsorption quality. The 
mixture is consistently adsorbed by mixing 
in a blender. This solid mixture is filled 
into capsule or added to more excipients 
before compression into tablets. The above 
mixture is solidified to powder forms 
using three kinds of adsorbents: micro 
porous calcium silicate (FloriteTMRE); 
magnesium aluminum silicate 
(NeusilinTMUS2) and silicon dioxide 
(SylysiaTM 320) [16, 17]. 
 
Spray Drying 
In this technique first the prepared 
formulation containing oil, surfactant, 
drug, solid carrier etc., is sprayed into a 
drying chamber through a nozzle. Small 
solid particles are left over after 
evaporation of the volatile vehicles. These 
particles are then filled into capsules or 
compressed into tablets. [16, 17]. 
Melt Extrusion 
This formulation technique depends on the 
property of the plastic mass material which 
can be easily extruded and sermonized 
with pressure. Here there is no need for 
addition of liquid form of excipients but a 
constant temperature and pressure need to 
be maintained [16, 17]. 
 
Dry Emulsion 
It is mainly O/W emulsion, which is then 
converted into solid form by spray 
drying/solid carrier/ freeze drying [16, 17]. 
 
DOSAGE FORMS OF SEDDS 
Self-Emulsifying Capsules 
It is a capsule containing liquid or 
semisolid form of self -emulsifying 
system. In the GIT, the capsules get 
dispersed to SES uniformly in the fluid to 
micron size, enhancing bioavailability. 
Another type of self -emulsifying capsule 
is solid SES which is filled into capsule. 
 
Self-Emulsifying Tablets 
S. Nazzal et al., developed self-nano 
emulsified tablet dosage form of 
Ubiquinone. The main objective of this 
work is to study effect of formulation 
ingredients on the release rate of 
Ubiquinone and to evaluate an optimized 
self-nano emulsified tablets formulation. 
The first prepared self-nano emulsion 
system containing Ubiquinone is prepared 
as nano emulsion, this nano emulsion is 
absorbed by granular materials and then 
compressed to form tablets. The optimized 
formulation of coenzyme Q10 self-nano 
emulsified tablet dissolution profile 
showed that 80‐90% drug release took 
place in 45 minutes. A.A. Attama et al., 
formulated the diclofenac delivery of solid 
self‐emulsifying systems. This solid self-
emulsifying system is developed using 
goat fat and tween. The fatty material and 
surfactant are heated together to melt and 
added to weighted quantity of drug and 
dissolved in the melt, this molten mass is 
then poured into plastic mould and cooled. 
Tablets which are formed possess property 
to liquefy at body temperature without 
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agitation, also under GIT conditions, 
peristaltic movement will lower the time 
of liquefaction which will then result in to 
faster emulsification addition to elevated 
concentration of plasma. Different 
formulation ratio possesses fluctuating 
dissolution profile at constant 
speed/agitation. These tablets showed 
good release profiles with acceptable tablet 
properties [18]. 
 
Self-Emulsifying Beads 
Self-emulsifying system can be formulated 
as a solid dosage form by using less 
excipient Patil and Paradkar discovered 
that deposition of SES into micro porous 
polystyrene beads is done by solvent 
evaporation. Porous polystyrene beads 
with complex internal void structures are 
typically produced by copolymer rising 
styrene and divinyl benzene. It possesses 
properties that it is inert and stable over a 
wide range of pH, temperature and 
humidity. Geometrical features, such as 
bead size and pore architecture of PPB, are 
found to govern the loading efficiency and 
in vitro drug release from SES‐loaded PPB 
[19]. 
 
Self-Emulsifying Microsphere 
Formulated solid sustained‐release 
microspheres using the emulsion solvent 
diffusion method for the spherical 
crystallization technique. Zedoary turmeric 
oil release behavior could be controlled by 
the ratio of hydroxyl propyl 
methylcellulose acetate succinate to 
Aerosil 200 in the formulation. 
Bioavailability attained after oral 
administration of such microshperes into 
rabbits was 135.6% with respect to the 
conventional liquid SEDDS. 
 
Self-Emulsifying Nanoparticles 
Nanoparticles technology can be applied to 
the formulation of self-emulsifying 
nanoparticle. In this method the prepared 
molten mass contained lipid, surfactant 
and drug. This lipid molten mass is 
injected drop wise into a non-solvent 
system. This is filtered and dried to get 
Nanoparticles. By this method, 100 nm 
size particles with 70−75% drug loading 
efficiency is obtained. 
 
Second technique is sonication emulsion 
diffusion evaporation; by this method co‐
load 5‐flurouraciland antisense EGFR 
(epidermal growth factor receptor) 
plasmids in to biodegradable PLGA/O‐
CMC nanoparticles. The mixture of PLGA 
(poly‐lactide‐coglycolide) and O‐CMC (O‐
carboxymethyl‐chitosan) had a SE effect, 
with no additional surfactant required. 
Trickler et al., developed a novel 
nanoparticle drug delivery system 
consisting of chitosan and 
glycerylmonooleate (GMO) for the 
delivery of paclitaxel (PTX). There is 
increased in cellular association due to its 
bio adhesion of chitosan/GMO 
nanoparticles, and it is prepared multiple 
emulsion (o/w/o) solvent evaporation 
methods [20, 21]. 
 
Self-Emulsifying Suppositories 
Some researchers have proven that Solid-
SEDDS might increase not only GI 
adsorption but also rectal/vaginal 
adsorption. Glycyrrhizin, has low 
therapeutic plasma concentration when 
given orally, hence one can obtain 
satisfactory therapeutic levels for chronic 
hepatic diseases by either vaginal or rectal 
SE suppositories. The formulation 
included glycyrrhizin and a mixture of a 
C6–C18 fatty acid glycerol ester and a C6–
C18 fatty acid macrogol ester [22]. 
 
Self-Emulsifying Sustained/Controlled-
Release Pellets 
To formulate and prepare SEDDS, there 
are some basic guidelines needed to 
conform: Safety, compatibility, drug 
solubility, efficient self-emulsification 
efficiency and droplet size, etc. There are 
several advantages of pellets over 
conventional solid dosages forms, which 
includes flexibility of manufacture, 
reduction of intra subject and inter subject 
variability of plasma pro-files and 
reducing GI irritation without altering low 
drug bioavailability. Thus, it seems very 
appealing to combine the advantages of 
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pellets with those of SEDDS by SE pellets. 
Spherical pellets with low friability and 
self-emulsifying properties can be 
produced by the standard 
extrusion/spherization technique. Pellets 
have high potential to increase the 
bioavailability of lipophilic drugs by 
transferring lipophilic compounds into the 
aqueous phase Formulation of SE 
controlled-release pellets by incorporating 
drugs into SES will increase the rate of drug 
release, water- insoluble polymer is used to 
coat the pellets which will then retard the rate 
of drug release, and will be more useful. 
Pellets are formed by extrusion/ spherization 
techniques and possess two water-insoluble 
model drugs (methyl and propyl parabens); 
SES contained mono-diglycerides and 
Polysorbate 80 the combinations of coating 
and SES might control in vitro drug release 
by providing a variety of release rates and the 
presence of the SEDDS did not influence the 
ability of the polymer film to control drug 
dissolution [23]. 
 
List of Drugs Mostly Used in SEEDS [24] 
Table 7: Drug which are commonly used in SEDDS preparation. 
Cyclosporin Halofantrine Silymarin Atorvastatin 
Ontazolast Vitamin E Itraconazole Atovaquone 
Coenzyme Q10 Simvastatin Seocalcitol Win 54954 
Biphenyl Dimethyl 
Dicarboxylate 
Indomethacin Ro-15-0778 PNU-91325 
Progesterone Tocotrienols 
Model Compounds including, 
Disopyramide, Ibuprofen, 
Ketoprofen, Tolbutamide 
Carvediol 
 
FACTORS AFFECTING SEDDS 
Concentration of Drug 
For any formulation, were drug is 
administer at high does they are not at all 
suitable for SEDDS, if they possess very 
good solubility in any one of the 
components, either hydrophilic or 
lipophilic but most preferable is lipophilic 
phase [25, 26]. 
 
Solubility of Drug 
Capacity of SEDDS to maintain the drug 
in solubilized form is greatly influenced by 
the solubility of the drug in oily phase. If 
the surfactant and co-surfactant contribute 
to a greater extent for solubilization then 
there is risk of precipitation [25, 26]. 
 
Polarity of Lipid Phase 
Major factor which governs the release of 
the drug from the micro-emulsion is 
polarity of lipid phase. To determine the 
polarity of droplet, there are certain 
techniques as follows: HLB scale, degree 
of unsaturation of fatty acid, chain length, 
molecular weight of hydrophobic portion 
and emulsifier concentration [25, 26]. 
 
Drug Solubility in Oil Phase 
The ability of SEDDS to maintain the drug 
in solubilized form is generally influenced 
by the solubility of the drug in oily phase. 
If the surfactant or cosurfactant is 
contributing to a greater extent of drugs 
Solubilization, then there could be a risk of 
precipitation, as dilution of SEDDS will 
lead to lowering of solvent capacity of 
surfactant or co-surfactant [25, 26]. 
 
Equilibrium Solubility 
Measurement can be carried out to 
anticipate potential cases of precipitation 
in the gut. However, crystallization could 
be slow in solubilizing environment of the 
gut. Pouton study reveals that such 
formulation can take up to 5 days to reach 
equilibrium and that the drug can remain 
in a super saturated state up to 24 hours 
after the initial emulsification event. It 
could thus be argued that such products are 
not likely to cause precipitation of the drug 
in the gut before the drug is absorbed, and 
indeed that super-saturation could actually 
enhance absorption by increasing the 
thermodynamic activity of the drug. There 
is a clear need for practical methods to 
predict the fate of drugs after the 
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dispersion of lipid systems in the gastro-
intestinal tract [25, 26]. 
 
Charge of Emulsion Droplets 
Numerous physiological studies have 
proved that the potential of absorptive 
cells, as well as that of all other cells in the 
body, is negatively charged with respect to 
the mucosal solution in the lumen. Benzoic 
acid had a dual function on the SEDDS; it 
could improve the self-emulsifying 
performance of self-emulsifying oily 
formulations (SEOF’S) and self-micro 
emulsifying oily formulations (SMEOF’S) 
in 0.1N HCL due to formation of a 
positively charged emulsion [25, 26]. 
 
TERNARY PHASE DIAGRAM 
Ternary diagrams are often constructed for 
the development of SEDDS that help in 
determining the optimum concentrations 
of different excipients necessary to obtain 
homogenous pre-concentrations self-
emulsification ability and drug loading 
each corner of ternary diagram represents 
100% of a particular component and when 
more than three components are used 
closely related ones are grouped tougher as 
one component and treated as such in the 
diagram they are generated by water 
titration method. 
 
In this method water is incorporated to 
SEDDS pre concentrate in drop wise 
manner with gentle stirring to allows 
equilibration addition of water leads to 
formulation of complex systems ranging 
from gel to systems containing lamellar, 
hexagonal or cubic phases to micro 
emulsions the mixture is visually 
examined for transparency the points from 
clear to turbid and turbid to clear as 
designated as emulsion and micro 
emulsion. 
 
Ternary phase diagram is applicable to 
construct the ideal composition range 
for three key excipients according to the 
subsequent droplet size following self-
emulsification, stability upon dilution 
and viscosity. Titration method is 
performed to construct phase diagram. 
At different ratios mixture of oil with 
surfactant is prepared (e.g. 10:0, 9:1, 
8:2, 7:3, 6:4, 5:5, 4:6, 3:7, 2:8, 1:9, 
0:10) into different vials. Minor amount 
of water in 5 % (w /w) is added into the 
vials. It is centrifuged for 2 to 3 minute 
and is incubated at 25⁰C or 48 hrs with 
gentle shaking [27]. 
 
Figure 4: Ternary phase diagram. 
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EVALUATION OF SEDDS 
Droplet Size and Particle Size 
Measurement 
This is a crucial factor in self- micro 
emulsification performance because it 
determines the rate and extent of drug 
release as well as the stability of the 
emulsion. The droplet size of the 
emulsions is determined by photon 
correlation spectroscopy (which analyses 
the fluctuations in light scattering due to 
Brownian motion of the particles) which 
can measure sizes between 10 and 5000 
nm. Light scattering is then monitored at 
25°C at a 90° angle. 
 
Particle size range of nano was used after 
100 times with water dilution, it possess 
compatibility with more water. 
 
Viscosity Determination 
The SEDDS system is generally 
administered in soft gelatin or hard gelatin 
capsules. Therefore, it should be easily 
pourable into capsules and such system 
should not be too thick to create a 
problem. The rheological properties of the 
micro-emulsions are evaluated by 
Brookfield Viscometer. This viscosity 
determination confirms whether the 
system is w/o or o/w 
 
Refractive Index and Percent 
Transmission 
To check the transparency of any 
formulation refractive index and percent 
transmittance is assed. The refractive 
index is measured by refractometer by 
placing drop of solution on slide and then 
it is compared with water. The percent 
transmittance of the system is measured at 
particular wavelength using UV Visible 
spectrophotometer keeping distilled water 
as blank. If there is similarity of refractive 
index of water and formulation then it 
possess percent transmittance>99 percent 
then formulation has transparent nature. 
 
Turbidimetric Evaluation 
To identify efficient self-emulsification by 
establishing whether the dispersion 
reaches equilibrium rapidly and in a 
reproducible time turbid metric is 
performed Nepheloturbidimetric 
evaluation is done to monitor the growth 
of emulsification. Fixed quantity of Self 
emulsifying system is added to fixed 
quantity of suitable medium (0.1N 
hydrochloric acid) under continuous 
stirring (50 rpm) on magnetic plate at 
ambient temperature and the increase in 
turbidity is measured using a turbidimeter. 
 
Dispersibility Test 
Dissolution apparatus standard USP XXII 
used to check the efficiency of self- 
emulsification of micro or nano emulsion. 
One milliliter of each formulation is added 
to 500 ml of water at 37 ±0.5°C. A 
standard stainless-steel dissolute rotating 
at 50 rpm provides gentle agitation. In-
vitro of formulations is then visually 
assessed using the following grading 
system.
 
Table 8: Grading system of in-vitro formulations. 
Grade Functions 
Grade A Nano emulsion Rapidly forming (within 1 min) having a clear or bluish appearance. 
Grade B Slightly less clear having a bluish white appearance rapidly forming 
Grade C Fine milky emulsion that forms time required to form is within 2 min. 
Grade D Color is Dull grayish white emulsion having slightly oily appearance that is slow to emulsify. 
Grade E This formulation possess either poor or minimal emulsification with large oil globules present 
on the surface. 
 
Stability Studies 
Physical stability of a lipid-based 
formulation is very much important to its 
performance, which can be unfavorably 
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inflated by precipitation of the drug in the 
excipients matrix. Moreover, physical 
stability can lead to excipient phase 
separation, also it may bear poor visual 
appearance. Gelatin capsule shell can lead 
to brittleness or delayed disintegration or 
no drug release from formulation if they 
possess incompatibilities. 
 
Heating Cooling Cycle: there are total six cycles between refrigerators temperature (4°C) and (45°C) 
with storage at each temperature of not less than 48 h is studied. Those formulations, which are stable at 
these temperatures, are then subjected to centrifugation process test  
Centrifugation: Above passed formulations are centrifuged thaw cycles between 21°C and 25°C with storage at 
each temperature for not less than 48 h is done at3500 rpm for 30 min. Those formulations that do not show any 
phase separation are taken for the freeze thaw stress test. 
Freeze Thaw Cycle: Three freeze thaw cycles for the formulations. Those formulations pass this test show good 
stability with no phase separation, creaming or cracking. 
 
Drug Encapsulation Efficiency 
The quantities of the drugs theoretically 
contained in the SEDDS are compared 
with the quantity actually obtained, from 
the drug content studies i.e. the quantity 
loaded into the SEDDS formulated. To get 
the drug encapsulation efficiency 
calculated by the following equation, 
EE (%) = ADC/TDC x 100 
Where, 
ADC is the actual drug content. 
TDC is the theoretical drug content. 
 
Yield of the SEDDS 
The SEDDS formed is filtered from the 
solvent, dried in the desiccators and 
weighed to get the yield of the SEDDS 
formulated per batch. Percentage yield can 
be calculated by formula,  
% recovery = W1/W2+W3x100 
Where, 
W1 is the weight of the SEDDS 
formulated. 
W2 weight of the drug added. 
W3 is the weight of the lipid and 
surfactant used as the starting material. 
 
Zeta Potential Measurement 
Zeta potential is applicable to determine 
the charge of the droplets. In conventional 
SEDDS, the charge on an oil droplet is 
negative due to presence of free fatty 
acids. 
 
Bioavailability Study 
Based on the self- emulsification 
properties, particle size data and stability 
of micro emulsion the formulation is 
selected for bioavailability studies. 
 
In-vivo drug quantification was performed 
of formulation after administration of 
drug. The plasma profiles of the drug in 
experimental animals following oral 
administration of the conventional tablet 
and SEDDS form are compared. 
Pharmacokinetic parameters for the drug 
following oral administration are 
calculated. The area under the 
concentration–time curve (AUC0→24h) is 
estimated according to the linear 
trapezoidal rule. The relative 
bioavailability (BA) of SEDDS form to the 
conventional table is calculated using the 
following Equation, Relative BA (%) = 
(AUC test / AUC reference) X (Dose 
reference / Dose test) [28−30].
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Table 9: Evaluation parameters, Instrument used and Purpose of Evaluation for SEDDS. 
Evaluation parameters Instrument used Purpose 
Size of Emulsion 
Droplet 
Coulter nano-sizer Self-emulsification dispersion performance. 
Turbidimetric 
evaluation 
 
Turbidimeter Identify efficient self-emulsification by establishing whether 
the 
dispersion reaches equilibrium rapidly and in a reproducible 
time. 
Viscosity determination Brookfield Viscometer Confirms whether the system is w/o or o/w. 
Refractive index Refractometer Transparency of formulation. 
Zeta potential 
 
Zeta meter To determine the charge, on droplets of emulsion it has 
practical application in stability of systems 
containing dispersed particles since this potential 
Dispersibility test 
 
USP XXII Dissolution 
apparatus 2 
Efficiency of self-emulsification. 
 
APPLICATIONS 
Super Saturable SEDDS (S-SEDDS) 
Due to high level of surfactant, this 
formulation may lead to GI side effects 
and a new class of super saturable 
formulations including super saturable 
SEDDS. (S-SEDDS) formulations is 
developed and designed from the purpose 
of reducing the side effects of surfactants 
and attain rapid absorption of poorly 
soluble drugs. The S-SEDDS formulations 
comprises of a reduced level of surfactant 
and a polymeric precipitation inhibitor to 
stabilize a drug in a temporarily super-
saturated state. Hydroxypropyl 
methylcellulose (HPMC) and related 
cellulose polymers are well recognized for 
their propensity to inhibit crystallization 
and, thereby, generate and maintain the 
supersaturated state for prolonged time 
periods Paclitaxel super saturable self- 
emulsifying drug delivery (S-SEDDS) was 
formulated using HPMC as a precipitation 
inhibitor. In vitro S-SEDDS formulation 
has results in formation of a micro 
emulsion, followed by slow crystallization 
of paclitaxel on standing. This result 
indicates that the system is supersaturated 
with respect to crystalline paclitaxel, and 
the supersaturated state is prolonged by 
HPMC in the formulation. In the absence 
of HPMC, the SEDDS formulation 
undergoes rapid precipitation, yielding a 
low paclitaxel solution concentration. A 
pharmacokinetic study showed that the 
paclitaxel S-SEDDS formulation produces 
approximately a 10-fold higher maximum 
concentration (Cmax) and a 5-fold higher 
oral bioavailability compared with that of 
the orally administered Taxol formulation 
(and the SEDDS formulation without 
HPMC A poorly soluble drug, PNU-
91325, was formulated as a super saturable 
SEDDS. The comparative in vitro studies 
indicated that the presence of a small 
amount HPMC in the formulation was 
critical to achieve a stabilized 
supersaturated state of PNU-91325 upon 
mixing with water. A S-SEDDS 
formulation composed of 30% w/w 
Cremophor (surfactant), 9% PEG 400, 5% 
DMA, 18% Pluronic L44, 20% HPMC, 
and other minor components had an oral 
bioavailability of ~ 76%, comparable with 
that of a neat Tween formulation 
(bioavailability: ~ 68%). Note that the 
weight ratio of drug to ctenophore EL is 
1:7.5 in the S-SEDDS formulation while 
the weight ratio of drug to Tween is 1:39 
in the neat Tween formulation. Applying 
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the super saturable SEDDS approach, a 
reduced amount of surfactant is 
deliberately used with HPMC in order to 
produce a temporarily supersaturated state 
with reduced solubilization. This is to 
obtain a high free drug concentration 
through generating and maintaining a 
supersaturated state in vivo and to increase 
the driving force for absorption. 
Significant reduced amount of surfactant 
used in S-SEDDS formulation provides a 
better toxicity/safety profile than the 
conventional SEDDS formulations [31, 
32]. 
 
Solid SEDDS 
SEDDS are normally prepared as liquid 
dosage forms that can be administrated in 
soft gelatin capsules, which have some 
disadvantages especially in the 
manufacturing process. Other method is 
the incorporation of liquid self-
emulsifying ingredients into a powder in 
order to create a solid dosage form 
(tablets, capsules). Progesterone 
formulation in SEEDS has been 
formulated by the process of 
extrusion/spherization for in vitro drug 
release (100% within 30 min, T50% at 13 
min). Progesterone same dose (16 mg) in 
pellets and in the SEDDS liquid 
formulation resulted in parallel AUC, 
Cmax and Tmax. The pellets produced 
with oil to surfactant ratio of 1:4 (w/w) 
showed improved performance in 
permeation experiments. At-tama et al. 
used goat fat and Tween 65 admixtures to 
formulate self-emulsifying tablets 
containing diclofenac by pour moulding 
using a plastic mould. The tablets showed 
good release profiles, as well as acceptable 
tablet properties. Under mild agitation, 
such as occurs under gastrointestinal 
conditions, the release rates are 
comparable with those of conventional 
tablets Encapsulating the emulsion lipid 
droplets in HPMC by spray-drying has 
been demonstrated to produce an improved 
bioavailability following release of the 
lipid droplets from the powder in vivo 
[33−39]. 
 
Tuel et al., has examined the oral 
bioavailability of a directly compressible 
dry emulsion as a tablet and compared it 
with an HPMC dry emulsion powder and a 
simple lipid solution. Four female Beagle 
dogs received a single dose of each 
formulation containing the same amount of 
MCT and model drug, Lu 28-179. 
Cyclodextrins solutions administered 
orally and intravenously were used as 
references [40]. 
 
The decrease in absolute bioavailability is 
in following order: starting with increasing 
order MCTsolution (0.06) < improved dry 
emulsion (0.10) < HPMC dry emulsion 
(0.11)< Cyclodextrin solution (0.14) The 
directly compressible dry emulsion tablets 
were concluded to be comparable with the 
HPMC dry emulsion powder in terms of 
bioavailability [33, 34]. 
 
Recent Approaches in SEDDS
 
 SEEDS for improving poor solubility 
[41]. 
 SEDDS of co-enzyme Q10 was 
prepared resulted in enhanced 
bioavailability and reduced toxicity 
[42]. 
 Lipophilic compound WIN 54954 was 
formulated as SEDDS in triglyceride 
oil/ nonionic surfactant mixtures and 
resulted in improved reproducibility of 
the plasma profile in terms of Cmax and 
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Tmax [43]. 
 Self-micro emulsifying drug delivery 
system (SMEDDS) of simavastin was 
developed to enhance its oral 
bioavailability. This study illustrated 
the potential use of SMEDDS for the 
delivery of hydrophobic compounds 
[44]. 
 A novel SEDDS of Paclitaxel (used for 
the treatment of solid tumors) was 
prepared and found that SEDDS was 
chemically stable for at least 1 year 
when kept as two part formulation and 
also the drug loading was increased by 
approximately 5fold compared to 
marketed IV formulation, the excipient 
presented a significantly reduced 
cytotoxicity and led to a stable micro 
emulsion [45]. 
 An antimalarial drug Halofantrine was 
prepared as SEDDS and SMEDDS and 
resulted in 8-fold improvement in 
absolute oral bioavailability relative to 
previous data of the solid [46]. 
 Enhanced bioavailability up to 1.88 of 
silymarin by self-micro emulsifying 
drug delivery system [47]. 
 Using SEDDS self-nano emulsified 
drug delivery system (SNEDDS) of 
ubiquinone was prepared and study 
revealed that SNEDDS overcome the 
drawbacks of the traditional emulsified 
system such as low solubility and 
irreversible precipitation of the active 
drug in the vehicle with time [48]. 
 The two novel SMEDDS containing 
Labrasol with different dilutions on 
tight junction was studied and found 
that Labrasol with concentration of 0.1 
and 1 % was shown to increase the 
permeability of mannitol by 4.6-fold 
and 33.8-fold respectively. 
 The solid self -emulsifying system was 
used in the delivery of diclofenac and 
result indicated that diclofenac could be 
comfortably administered in the form of 
self-emulsifying tablets using goat fat 
and Tween 65 admixtures [49]. 
 SEDDS containing Ketoprofen was 
formulated as sustained release dosage 
form and found that drug released was 
increased. [50] 
 
Future of Self-Emulsified Drug Delivery 
System 
More than 40% of new drugs exhibit poor 
aqueous solubility and SEDDS are a 
promising approach for the formulation of 
these drugs. The development of SEDDS, 
however, is still largely empirical, and in 
vitro models that are predictive of oral 
bioavailability enhancement are lacking.  
 
There is a necessity for in vitro methods 
for forecasting the dynamic changes 
involving the drug in the gut in order to 
monitor the solubilisation state of the drug 
in vivo. Attention also needs to be paid to 
the interactions between lipid systems and 
the components of the capsule shells. The 
characteristics of various lipid 
formulations also need to be understood, 
so that guidelines can be established that 
allow identification of suitable candidate 
formulations at an early stage. Future re-
search should involve human 
bioavailability studies, as well as more 
basic studies on the mechanisms of action 
of this fascinating and diverse group of 
formulations.
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PATENTS 
Table 10: Patent of SEEDS [51]. 
1) U S PATENT 
Patent No. 20100266683 
Issued on Oct 21 2010 
Inventor Christina Holmberg (Sodertalje, SE) Britta Siekmann (Lomma) 
Assignee Nicox S.A. 
Title New self emulsifying drug delivery system 
Description 
The present invention claims and discloses a pharmaceutical composition for oral 
administration in form of an emulsion preconcentrate comprising 
1. A active compound. 
2.one or more surfactants 
3.optionally an oil or semi solid fat said composition forming an in situ oil in water emulsion 
upon contact with aqoues media such as gastrointestinal fluids the composition may optionally 
also comprise one or more short chain alcohols. Use din pain and inflammation. 
2) U.S. PATENT 
Patent No. US4255431 
Filling Date Apr 5, 1979 
Issued on Mar 10,1981 
Inventor Christina Holmberg  
Assignee Nicox S.A. 
Title 
Gastric acid secretion inhibiting substituted 2-(2benzimidazolyl)-pyridines, pharmaceutical 
preparations containing same, and method for inhibiting gastric acid secretion 
3) U.S. PATENT 
Patent No. US20100113376A1 
Filling Date Apr 17,2008 
Issued on 2010 
Inventor Franz x.schwarz,worgl (AT) 
Title Process for dosing self-emulsifying drug delivery systems 
Description 
The present invention provides process for dosing a self – dispersing drug delivery 
system comprising an active compound said process comprising the step of using a 
dosage dispenser to dose a defined amount of said self – dispersing drug delivery 
system comprising an active compound and dosage dispenser containing a self – 
dispersing drug delivery system comprising an active compound 
4) U.S. PATENT 
Patent No. US 2002/0119198 A1 
Filling Date Jul 20, 2001 
Issued on Aug 29, 2002 
Inventor Ping Gao,Walter Morozowich, Narmada Shenoy 
Title 
Self-emulsifying drug delivery system for extremely water insoluble, lipophillic 
drugs 
Description 
A formulation for administering an extremely water-insoluble active agent is 
disclosed. more particularly, a self emulsifying drug delivery system for extremely 
water-insoluble, lipophilic compounds is disclosed 
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REVIEW OF WORK DONE 
Table 11: Different drug studies using SEDDS. 
Drug Oil Surfactant 
Cosolvent/ 
Cosurfactant 
Improvement 
Ketoprofen Captex 200 Tween 80 Capmul MCM 
Silicon dioxide is used for the 
gelling agent, as the 
concentration of silicon 
dioxide is increases, it causes 
the increase in the droplet size of the 
emulsion and shows slow diffusion 
carvediol Lab’ [rasol] 
Labrafil M 
1944 CS 
 
Transcutol P 
It increases oral bioavailability 
carvediol up to 413% when 
compared to conventional tablets. 
Itraconazle 
Tocophero 
l aceteate 
Pluronic L64 Transcutol P 
Itraconazle SEDDS formulation 
shows enhanced bioavailability 
without influence of food. 
Coenzyme Q 
Captex 
200 and 
Myvacet 
9-45 
Labrasol and 
Labrafac 
CM-10 
Iauroglycol 
Medium chain oils and Myvacet 9-
45 provides higher solubility to 
coenzyme Q than long chain oils 
SEDDS 
provides two-fold increase in 
bioavailability than the powder 
formulations 
1,3-Bis(2 
chloroethyl 
) 1nitrosourea 
(BCNU) 
Tributyrin 
cremophor 
e RH 40 
Labrafil 1944 
SEDDS increases the in vitro half-
life of BCNU up to 130 
min compared to 45 min of intact 
BCNU. 
Drug Name Dosage form Brand name/Company 
Amprenavir SG capsule Agenerase/GlaxoSmithKline 
Bexarotene SG capsule Targretin/Ligand 
Calcitriol 
SG capsule, 
solution 
RocaltrollRoche 
 
Carvedilol phosphate CR HG capsule Coreg CRI /GlaxoSmithKline 
Ciprofloxacin 
Microcapsules 
for suspensions 
Cipro/Bayer 
 
Cyclosporin A 
 
SG capsules, oral 
suspensions 
NeorallNovartis Sandimmune/Novartis suspensions 
 
Dronabiol 
SG capsules 
 
MarinollRoxane and Unimed 
Avodart/GSK 
Dutasteride SG capsule Lipofen/Kowa Pharmaceuticals 
Fenofibrate SG capsule America, Inc. 
Isotretinoin HG capsule Accutane/Roche 
Lopinavir and 
Ritonavir 
SG capsule Kaletra/Abbott 
Mesalamine 
Tablet, SG 
capsule 
Pentasa/Shire US inc. 
Omega-3-acid 
esters 
CR-capsules 
 
Lovaza/GSK 
 
Paricalcitol HG capsule Zemplar/Abbott Labroratories 
Saquinavir SG capsule Fortovase/Roche 
Sirolimus SG capsule Rapamune/Wyeth-Ayerst 
Tipranavir 
Tipranavir 
Oral solution 
SG capsule 
Aptivus/Boehringerllngelheim 
Aptivus/Boehringerllngelheim 
Tolterodine tartrate ER HG capsule Detrol /LNPharmacia 
Tretinoin SG capsule Vesanoid/Roche 
Valproic acid SG capsule Depakene/Abbott 
  
41 Page 19-44 © MAT Journals. All Rights Reserved 
 
Recent Trends in Pharmaceutical Sciences and Research  
Volume 2, Issue 1 
 
CONCLUSION 
Self-emulsifying drug delivery systems is 
novel approach in the formulation of any 
drug whose solubility is poor. For 
hydrophobic drugs, the oral delivery can 
be made by SEDDSs, this formulation 
further possess good bioavailability. This 
novel technology of SEEDS’S will solve 
problems with drug delivery of drug who 
have poor solubility. Numerous studies 
have confirmed that SEDDS substantially 
improved solubility/dissolution, absorption 
and bioavailability of poorly water‐soluble 
drugs. As improvements or alternatives of 
conventional liquid SEDDS. These are 
superior in reducing production cost, 
simplifying industrial manufacture, and 
improving stability as well as patient 
compliance. Most importantly, SEDDS are 
very flexible to develop various solid 
dosage forms for oral and parenteral 
administration. Also there is advantage of 
no GI irritation and formulation can be 
sustained release/ controlled release. There 
is still a long way to go, however, before 
more solid SEDDS dosage forms (except 
for SE capsules) appear on the market. 
Because there exist some fields of SEDDS 
to be further exploited, such as studies 
about human bioavailability and 
correlation of In vitro/In vivo. That is 
SEDDS implants/suppositories/microspher
es have not been as extensively studied as 
SEDDS tablets/pellets/capsules. It is also 
worth pointing out some issues to which 
much attention should be paid, for 
example physical aging phenomenon 
associated with glycerides, oxidation of 
vegetable oil, and interaction between 
drugs and excipients Selection of suitable 
excipients is the main hurdle of developing 
SEDDS. Thus, these aspects should 
represent the major future working 
directions for SEDDS. Thus, major 
breakthroughs are still required for proper 
development of SEDDS. 
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